YAP1 Rearrangement in Parotid Sclerosing Mucoepidermoid Carcinoma

References

• Sekine S, Kiyono T, Ryo E, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129:3827–5. doi:10.1172/JCI126185.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Salinas Parra N, Chen Q, et al. Oncogenic hedgehog-smoothened signaling depends on YAP1‒TAZ/TEAD transcription to restrain differentiation in basal cell carcinoma. J Invest Dermatol. 2022;142(1):65–76.e7. doi:10.1016/j.jid.2021.06.020.
   PubMed Web of Science ®Google Scholar
• Agaimy A, Stoehr R, Tögel L, et al. YAP1-MAML2-rearranged poroid squamous cell carcinoma (squamoid porocarcinoma) presenting as a primary parotid gland tumor. Head Neck Pathol. 2021;15:361–367. doi:10.1007/s12105-020-01181-9.
   PubMed Web of Science ®Google Scholar
• Kervarrec T, Frouin E, Collin C, et al. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma. Histopathology. 2023;82(6):885–898. doi:10.1111/his.14874.
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Ogawa K, Goto K, et al. YAP1::MAML2 fusions in poromatosis: a report of two patients. J Cutan Pathol. 2023;50(8):695–701. doi:10.1111/cup.14401.
   PubMed Web of Science ®Google Scholar
• Hu X, Xin Y, Xiao Y, et al. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res. 2014;20(4):805–811. doi:10.1007/s12253-014-9757-y.
   PubMed Web of Science ®Google Scholar
• Zhang L, Song X, Li X, Wu C, Jiang J. Yes-associated protein 1 as a novel prognostic biomarker for gastrointestinal cancer: a meta-analysis. Biomed Res Int. 2018;2018:1–10. doi:10.1155/2018/4039173.
   Web of Science ®Google Scholar
• Liu J, Zhao X, Wang K, et al. A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma. Cell Death Dis. 2019;10(6):10. doi:10.1038/s41419-019-1674-2.
   Google Scholar
• Giraud J, Molina-Castro S, Seeneevassen L, et al. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells. Int J Cancer. 2020;146:2255–2267. doi:10.1002/ijc.32667.
   PubMed Web of Science ®Google Scholar
• Molina-Castro SE, Tiffon C, Giraud J, et al. The hippo kinase LATS2 controls Helicobacter pylori-induced epithelial-mesenchymal transition and intestinal metaplasia in gastric mucosa. CMGH. 2020;9(2):257–276. doi:10.1016/j.jcmgh.2019.10.007.
   Google Scholar
• Kajo K, Othman B, Macháleková K. Sclerosing Warthin-like mucoepidermoid carcinoma of the salivary gland. Oral Oncol. 2022;134:134. doi:10.1016/j.oraloncology.2022.106090.
   Web of Science ®Google Scholar
• Wang C, Cheng L, Song S, et al. Gli1 interacts with YAP1 to promote tumorigenesis in esophageal squamous cell carcinoma. J Cell Physiol. 2020;235:8224–8235. doi:10.1002/jcp.29477.
   PubMed Web of Science ®Google Scholar
• He Q, Lin Z, Wang Z, et al. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene. 2020;39:7279–7295. doi:10.1038/s41388-020-01500-y.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zheng Y, Chen F, et al. Activation of YAP1 by STK25 contributes to the progression of hepatocellular carcinoma. Tissue Cell. 2022;76. doi:10.1016/j.tice.2022.101797.
   Web of Science ®Google Scholar
• Warmke LM, Meis JM. Sclerosing epithelioid fibrosarcoma: a distinct sarcoma with aggressive features. Am J Surg Pathol. 2021;45(3):317–328. doi:10.1097/PAS.0000000000001559.
   PubMed Web of Science ®Google Scholar
• Eun YG, Lee D, Lee YC, et al. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget. 2017;8(67):111130–111143. doi:10.18632/oncotarget.22666.
   PubMedGoogle Scholar
• Massoth LR, Hung YP, Nardi V, et al. Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions. Mod Pathol. 2020;33(11):2307–2317. doi:10.1038/s41379-020-0582-4.
   PubMed Web of Science ®Google Scholar
• Vivero M, Davineni P, Nardi V, et al. Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. Mod Pathol. 2020;33:560–565. doi:10.1038/s41379-019-0382-x.
   PubMed Web of Science ®Google Scholar
• Cordier F, Ameloot E, Dhooge C, et al. Spindle cell/sclerosing rhabdomyosarcoma with a novel YAP1-MAML2 fusion in a 1-year-old: not all strongly TRK-expressing spindle cell sarcomas in infants are infantile fibrosarcomas! Pathology. 2021;53(7):936–939. doi:10.1016/j.pathol.2021.02.009.
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Li BK, Souweidane MM, et al. YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma. Acta Neuropathol Commun. 2022;10(1):10. doi:10.1186/s40478-022-01423-7.
   PubMed Web of Science ®Google Scholar
• Omori H, Sato K, Nakano T, et al. Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness. J Cancer Res Clin Oncol. 2019;145(10):2433–2444. doi:10.1007/s00432-019-02995-z.
   PubMed Web of Science ®Google Scholar
• Sun Z, Xu R, Li X, et al. Prognostic value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis. PloS One. 2015;10(8):10. doi:10.1371/journal.pone.0135119.
   Web of Science ®Google Scholar
• Elham F, Mandour E. Towards a Synergistic Grading System for Mucoepidermoid Carcinoma. Advances in Clinical and Experimental Dentistry. 2023;4(2):3–14. doi:10.21608/aced.2023.232002.1022.
   Google Scholar